Efficacy and Safety of Antimicrobial Durations Treatment of Infections Associated With Osteosynthesis Material

Infections Clinical Trial

— DURATIOM  

Official title:

Efficacy and Safety of Different Antimicrobial Durations for the Treatment of Infections Associated With Osteosynthesis Material Implanted After Long Bone Fractures (DURATIOM). Phase 3 Pragmatic Multicenter Open Labelled Randomized Trial.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05294796
• Other study ID #: DURATIOM
• Status: Recruiting
• Phase: Phase 3
• Start date: August 9, 2022
• Est. completion date: April 2026

Study information

• Verified date: February 2023
• Source: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
• Contact: Clara Rosso Fernández
• Phone: 955012144
• Email: clara.rosso.sspa[@]juntadeandalucia.es
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Infections associated with osteosynthesis material are among the most feared and challenging complications of trauma surgery and can lead to total function loss or limb amputation when complete recovery is to be expected without infection.

This is a clinical trial with the purpose of evaluate the optimal duration of antibiotic therapy in Infections Associated With Osteosynthesis Material Implanted when implant is retained.

Description:

Orthopedic implants for fracture fixation or osteosynthesis material are used for internal fixation of fractures, allowing their stability and consolidation.

Infection associated with osteosynthesis material is one of the most feared and challenging complications of trauma surgery and can lead to total loss of function or amputation of the limb, when complete recovery is to be expected without infection. Furthermore, they involve excessive consumption of antimicrobials, with inadequate prescriptions and prolonged durations that favour superinfections by multidrug-resistant microorganisms, in addition to the drug-related toxicities, especially diarrhea due to Clostridium difficile. Most studies and recommendations on the management of orthopedic implant-associated infections have focused on prosthetic joint infections, and while they share similarities with Infections Associated With Osteosynthesis Material Implanted, there are major differences in terms of risk factors, diagnosis, treatment, and prevention. While the extrapolation of knowledge from prosthetic joint infections to the field of Infections Associated With Osteosynthesis Material Implanted has helped orthopedic surgeons and internists/infectologists in their management, there are large gaps and unanswered questions that represent a new challenge for research in this field. One of these challenges, and focusing on the field of infection treatment, is the search for the best surgical procedure according to the age of the implant and fracture healing, to determine the duration of antibiotic treatment and whether it should be maintained until fracture healing, and which is the most appropriate treatment in each of the scenarios.

The identification of conditions in which the duration of the antimicrobial treatment can be shortened, and in case of prolonged treatments, which antimicrobial has the best safety profile and less impact on the induction of bacterial resistances is of special interest, due to the frequent appearance of toxicities and the increase of bacterial resistances and superinfections by multidrug-resistant bacteria.

If the hypothesis of non-inferiority of short vs. long antibiotic treatments is demonstrated, and the efficacy of antibiotics with less ecological impact in long treatments, the impact on reduction of bacterial resistance, toxicity and health costs will be observed. The project also aims to promote quality and multidisciplinary care, homogenising clinical practice in the management of Infections Associated With Osteosynthesis Material Implanted based on scientific knowledge. Early and personalised patient care with Infections Associated With Osteosynthesis Material Implanted allows for faster recovery, both clinically and functionally, enabling earlier mobility recovery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 364
• Est. completion date: April 2026
• Est. primary completion date: April 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years and older

Eligibility

Inclusion Criteria:

• Age greater than or equal to 14 years.

• Stable fracture, even if unconsolidated.

• Controlled infection (absence of signs or symptoms of sepsis).

• Early or delayed infection.

• Availability of antibiotics active against the isolated microorganism.

• Absence of bone exposure. Patients who initially had bone exposure but during the debridement surgery bone coverage was performed by any method (skin approximation, grafting, vacuum therapy) can be included in the criteria.

• Signed written informed consent.

• If there is a possibility of pregnancy (in women of childbearing potential) or paternity, agree to use a highly effective method of birth control recommended by the Clinical Trial Facilitation Group (CTFG) during the treatment phase of the trial

Exclusion Criteria:

• Late infections

• Infections of revision osteosynthesis material or occurring after previous surgeries.

• Patients who are not expected to be followed up for at least 1 year after completion of antibiotic treatment.

• Pregnant or lactating women.

• Patients in whom there may be drug interactions or contraindications described in the technical data sheets of the investigational drugs used in this trial.

Related Conditions & MeSH terms

• Communicable Diseases
• Infections

Intervention

Combination Product:
• Short course of antibiotherapy
Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
• Long course of antibiotherapy
Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material

Locations

Country	Name	City	State
Spain	Hospital Universitario Príncipe de Asturias	Alcalá De Henares	Madrid
Spain	Hospital Universitario de Cruces	Barakaldo	Vizcaya
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Hospital Universitari de Bellvitge	Barcelona
Spain	Hospital Universitario Clinic de Barcelona	Barcelona
Spain	Hospital Universitario Vall d'Hebron	Barcelona
Spain	Hospital Universitario Puerto Real	Cádiz
Spain	Hospital San Pedro	Logroño	La Rioja
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Hospital Costa del Sol	Málaga
Spain	Hospital Regional Universitario de Málaga	Málaga
Spain	Hospital Universitario Virgen de la Victoria	Málaga
Spain	Hospital Universitari Son Espases	Palma	Illes Balears
Spain	Hospital Universitario El Bierzo	Ponferrada	León
Spain	Hospital Parc Taulí	Sabadell	Barcelona
Spain	Hospital Universitario Marqués de Valdecilla	Santander	Cantabria
Spain	Hospital Universitario Virgen de Valme	Sevilla
Spain	Hospital Universitario Virgen del Rocío	Sevilla	Seville
Spain	Hospital Universitario Virgen Macarena	Seville
Spain	Hospital Clínico Universitario Lozano Blesa	Zaragoza

Sponsors (1)

Lead Sponsor	Collaborator
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with clinical cure in the test of cure	A success at the test of cure is the resolution of infection symptoms, the absence of clinical signs and symptoms of infection (persistence of symptoms of infection, relapse of infection after a period without symptoms, or superinfection by a different microorganism) without antibiotic therapy and with C-reactive protein <10 mg/L (unless another cause justifies a higher C-reactive protein value); If the patient dies, when the death was not related to the infection; and no need for chronic suppressive antibiotic therapy to "control" of the infection.	12 months after completion of antimicrobial treatment
Primary	Radiological healing in the test of cure	Radiological healing is defined as the presence of radiological signs of fracture consolidation (plain radiographic or CT) of the infected bone. Non-union or absence of consolidation of a fractured bone is defined when it has not completely healed within 9 months after osteosynthesis surgery or when it has not shown progression towards fracture callus formation in 3 consecutive months on serial radiographs	12 months after completion of antimicrobial treatment
Primary	Definitive soft tissue coverage at test of cure	Number of patients who present definitive soft tissue coverage at test of cure	12 months after completion of antimicrobial treatment
Secondary	Presentation of adverse events (frequency and severity).	To evaluate the presentation of adverse events (frequency and severity) during the study.	Through study completion (12 months)
Secondary	Performance of an antibiogram to assess the development of antimicrobial resistance	Standard microbiological techniques will be used to identify microorganisms recovered and to determine antimicrobial susceptibility according to EUCAST recommendation (EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance, Version 2.0, 2017) https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf	8 months and 12 months
Secondary	Surgical wound culture to assess the development of secondary infections	To evaluate the appearance of secondary infections during antibiotic treatment that standard microbiological techniques will be used to identify microorganisms recovered and to determine antimicrobial susceptibility according to EUCAST recommendation (EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance, Version 2.0, 2017) https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf	8 months and 12 months
Secondary	Recurrence rate	To evaluate the recurrence rate during antibiotic treatment.	8 months and 12 months
Secondary	Evaluate the need for new surgeries, such as debridement, removal of material, coverage or amputation, through radiological evaluation of fracture union.	To evaluate the need for new surgeries through radiological evaluation	Day 28, week 8, week 12, month 6 and month 12.
Secondary	Evaluation of the functional status, defined as the recovery of the functionality of the limb prior to the fracture, by completing the Quick Disabilities of Arm, Shoulder and Hand questionnaire.	The functional state, normal or reduced, will be evaluated with respect to the situation prior to the fracture. Lower extremity mobility is classified as: walks unassisted; with 1 cane; with 2 canes; with walker; "wander home alone"; not wandering..	6 months and 12 months (visit 6 and 7)